Precision Medicine is the current major trend to maximize health outcomes in chronic medical conditions. This means that the time of “one drug for all” is over, instead, human diversity responses must be considered. Different patients need different drugs, and this is the driver of new medical management.
Chronic inflammation is the “poor sister” of the big human diseases family. Infectious diseases, cancer, and many other diseases have been managed under precision medicine protocols for decades. Culture and antibiograms are mandatory to prescribe antibiotics, and nowadays nobody thinks of cancer treatment without biomarkers and targeted therapies. On the contrary, chronic inflammation remains treated with immunosuppressive drugs mostly based on clinical guidelines, drug blood levels and trial/error approaches.
Inflammatory diseases are clearly lacking a tool to determine the potency (efficacy) of immunosuppressive drugs over the immune cells of the patients, which are actually the target cells of the immunosuppressants/ immunomodulators. This assay is able to identify those immunosuppressants that may be more efficacious for each patient at a specific point in time.